Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Scott Gottlieb

FDA Announces Comprehensive Regenerative Medicine Policy Framework

Washington, DC, November 20, 2017 — The U.S. Food and Drug Administration (FDA) on November 16 announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework – outlined in a suite of four guidance documents – builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products.

Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. Continue reading

Senate Confirms Dr. Scott Gottlieb to Head FDA with 57-42 Vote

Dr. Scott Gottlieb

Washington, DC, May 10, 2017 — The Senate voted 57 to 42 on Tuesday to confirm Dr. Scott Gottlieb as commissioner of the Food and Drug Administration (FDA), where he will be responsible for regulating drug companies to which he has had close ties in recent years.

Senators Robert Menendez (D-NJ) and Cory Booker (D-NJ) voted against Dr. Gottlieb’s nomination.

Dr. Gottlieb, 44, has promised to divest himself from several health care companies and recuse himself for one year from decisions involving those businesses. Continue reading

White House Announces President Trump to Select Dr. Scott Gottlieb to Head FDA

Scott Gottlieb, M.D.

Washington, DC, March 13, 2017 —Laurie McGinley and Carolyn Y. Johnson report in The Washington Post that President Donald J. Trump announced on March 10 that he will nominate Scott Gottlieb, a conservative physician and businessman with deep ties to the pharmaceutical industry, to be commissioner of the Food and Drug Administration.

If confirmed, Gottlieb would bring a strong pro-industry, deregulatory approach to an agency that Trump has criticized as being overly restrictive.

But he is also likely to support one of the agency’s basic functions: to ensure that drugs are proven safe and effective before they are sold. Continue reading